Apr 20, 2021
Leo Grady, Paige, on transforming precision medicine through AI
Stay updated on releases: subscribe on the Spotify, Apple, Twitter, or Stitcher.
In this episode, we meet Leo Grady, CEO of Paige. Paige is a global leader in AI-based software in pathology with a mission to drive the future of precision medicine. Paige is committed to transforming the diagnostics space by building an industry-leading portfolio of AI-based clinical applications, biomarkers and diagnostics.
Paige recently closed a $125 million Series C round, co-led by Casdin Capital, Johnson & Johnson Innovation and KKR, bringing the company’s total funding to $220 million since its launch in 2018. Paige has been honored as one of Fierce Medtech’s 2020 Fierce 15 companies and a New York Healthcare Innovation: Digital Health 100 Company.
Prior to joining Paige, Leo was the Senior Vice President of Engineering at HeartFlow, a medical technology company transforming the way cardiovascular disease is diagnosed and treated. Leo spent his early career at Siemens as a Principal Research Scientist and Line Manager, focusing on applying AI in clinical applications such as in vitro diagnostics. He holds a Ph.D. in Cognitive and Neural Systems from Boston University and a bachelor’s from the University of Vermont.
In this episode, Leo and I chat about:
- The founding story of Paige and collaboration with Memorial Sloan Kettering Cancer Center
- The trends and opportunities for digital innovation in the oncology pathology space, from screening/diagnosis to treatment selection and follow-up / monitoring
- How Paige’s AI technology platform, built on millions of digitized tumor slides, enables pathologists to increase their diagnostic confidence and productivity
- Leo’s reflections on driving change in healthcare
